Pent-Up Demand As GW Pharma’s Epidyolex Approved In Europe
Executive Summary
Drug will meet pent-up demand in Europe for clinically proven cannabis-based medicine for hard-to-treat epilepsy.
You may also be interested in...
NICE Says Initial No To Epidyolex In England, But GW Pharma Remains Upbeat
Draft guidance from NICE has recommended against the use of GW Pharmaceuticals’ Epidyolex for refractory epilepsy, but the company believes it has the data needed to ensure a positive outcome to the appraisal.
US FDA Filing Mistake For Fintepla Dents Zogenix
Zogenix seems only to have itself to blame for an unexpected refusal to file letter from the US agency for its novel treatment for Dravet syndrome that sent its shares tumbling by 31% on NASDAQ in after-hours trading.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.